Table 5:
Adjusted
1
hazard ratios for disease-specific and recurrence free survival.
2
Risk Factors
Oral cavity
Oropharynx
Disease-specific Survival
1
Recurrence-free survival
1
Disease-specific survival
1
Recurrence-free survival
1
HR (95% CI)
HR (95% CI)
HR (95% CI)
HR (95% CI)
Patients with HPV serology (
𝑁
=
1
8
2
)
𝑁
=
1
1
6
𝑁
=
9
6
𝑁
=
5
2
𝑁
=
4
3
E6 and/or E7
n
n
n
n
Negative
103 (88.8)
1.3 (0.4–4.2)
86 (89.6)
1.1 (0.3–3.6)
16 (30.8)
5.7 (1.7–20.0)
13 (30.2)
6.7 (1.7–26.1)
Positive
13 (11.2)
1.0
10 (10.4)
1.0
36 (69.2)
1.0
30 (69.8)
1.0
Age
2
1.02 (1.0–1.1)
1.02 (1.0–1.04)
1.04 (0.96–1.1)
1.03 (0.95–1.1)
Stage
0/I/II
1.0
1.0
1.0
1.0
III/IV
7.9 (2.8–22.5)
1.5 (0.7–3.1)
1.5 (0.2–11.4)
3
1.3 (0.03–58.8)
Patients with both HPV tumor and serology (
𝑁
=
1
5
7
)
𝑁
=
1
0
0
𝑁
=
8
8
𝑁
=
4
4
𝑁
=
3
9
E6 and/or E7
n
n
n
n
Negative
89 (89.0)
1.4 (0.4–4.5)
80 (90.9)
1.1 (0.3–3.5)
14 (31.8)
4.2 (1.2–15.1)
12 (30.8)
10.4 (2.4–52.4)
Positive
11 (11.0)
1.0
8 (9.1)
1.0
30 (68.2)
1.0
27 (69.2)
1.0
HPV tumor status
Negative
88 (88.0)
0.8 (0.3–2.0)
78 (88.6)
0.5 (0.2–1.3)
17 (38.6)
3.0 (0.9–10.7)
15 (38.5)
7.3 (1.5–36.4)
High Risk
12 (12.0)
1.0
10 (11.4)
1.0
27 (61.4)
1.0
24 (61.5)
1.0
1
Adjusted for stage and continuous age;
2
in years;
3
odds ratio Logit estimator adjusted for stage and categorical age.